RNTX

NASD Rein Therapeutics, Inc

Nov 4, 2026 · 1:58 PM ET DELAYED Market Open

$0.6709 ↑ +0.0033 (+0.50%) Trading Up from the previous close of $0.6675, $0.0575 below the day’s high of $0.7283

YTD change: -42.17%
vs 20-day SMA: +0.47%
vs 200-day SMA: -35.08%

Price ranges

Previous day

$0.6341 $0.7050

open $0.6680 close $0.6675

-$0.0005 (-0.07%)

Today

$0.6653 $0.7283

open $0.6877 now $0.6709

-$0.0169 (-2.45%)

Past week

$0.6200 $0.7495

from $0.7042 now $0.6709

-$0.0334 (-4.74%)

Past month

$0.5401 $0.8250

from $0.8250 now $0.6709

-$0.1542 (-18.68%)

This year

$0.5401 $2.1000

from $1.1600 now $0.6709

-$0.4892 (-42.17%)

Price & Performance

-0.35 (-34.56%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good

The stock is 80.8% away from all-time highs of $3.5000
RNTX is down 42% since the beginning of the year
RNTX is down 53% over the past 12 months
RNTX is down 19% over the past 1 month
1% of all RNTX investors are betting against RNTX

RNTX reads not so good: price sits above one of the two key moving averages, the 12-month move is -53.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.1

Earnings momentum N/A Quarterly EPS growth

Quarterly change N/A

Valuation

P/E ratio N/A

Enterprise value $49.1M

Beta 2.12

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$40.6M

DebtN/A

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $57.9M

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$461.26	-0.90%
MRNA	Moderna, Inc.	$228.44	+3.45%
RVMD	Revolution Medicines, Inc.	$194.23	+3.22%
ROIV	Roivant Sciences Ltd.	$36.04	+0.42%
BNTX	BioNTech SE Sponsored ADR	$86.92	-0.70%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.